PIROUETTE logo

PIROUETTE

A randomised, double-blind, placebo-controlled, phase 2 study of the efficacy and safety of PIRfenidOne in patients with heart f

PIROUETTE

A randomised, double-blind, placebo-controlled, phase 2 study of the efficacy and safety of PIRfenidOne in patients with heart f
Funding NIHR
Portfolio Clinical Specialties
Interventions Medicine
Randomised Yes
Status In follow-up
Start Date 01-Mar-2016

This clinical trial has been designed to test whether a drug called pirfenidone leads to a reduction in heart muscle scarring and improves heart function in patients with heart failure.
Taking part involves 11 visits to the hospital and 1 telephone call. Study tests include: blood tests, heart trace (ECG), echo (ultrasound scan of your heart), heart magnetic resonance imaging (MRI scan of your heart), short questionnaire, walk test. Females of child bearing age will need to have regular pregnancy tests and there will be additional phone calls to check the results of the pregnancy tests.

Publications

  • Lewis, G.A., Schelbert, E.B., Naish, J., Bedson, E., Dodd, S., Eccleson, H., Clayton, D., Duran B., McDonagh, T., Williams, S.D., Cooper, A., Cunnington, C., Ahmed, F., Viswesvaraiah, R., Russell, S., Neubauer, S., Williamson, P., and Miller, C. Pirfenidone in Heart Failure With Preserved Ejection Fraction - Rationale and Design of the PIROUETTE Trial. (accepted for publication) Cardiovascular Drugs and Therapy.
    1. https://doi.org/10.1007/s10557-019-06876-y